Sees Q4 adjusted EBITDA $14M-$17M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HIMS:
- Hims & Hers (NYSE:HIMS) Soars on Healthy Q3 Performance
- Hims and Hers Health options imply 14.4% move in share price post-earnings
- HIMS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Hims & Hers appoints Khobi Brooklyn as CCO
- HealthEquity price target raised to $110, named a ‘Best Idea’ at Guggenheim